Dated values
HSA post-marketing vigilance guidance Version 6
HSA post-marketing vigilance guidance Version 6
Record details
- Value
- HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references
- Unit
- guidance revision
- Value type
- observation
- Population
- Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore
- Denominator
- Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable
- Reference period
- Version 6 uploaded 1 April 2026
- Retrieved
- 2026-09-02
- Published
- 2026-04-01
- Geography
- sg.geo.country.singapore
Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force.
Sources
Collection as of 2026-10-07 · An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.